More then half of adults with severe alopecia areata-an autoimmune condition causing hair loss-regained substantial hair growth within a year of treatment with baricitinib, a new study shows. It’s a significant step forward for a condition that often defies conventional therapies.
baricitinib Shows Promise for Severe Hair Loss
A real-world study confirms the effectiveness and safety of baricitinib for adults struggling with alopecia areata.
- Baricitinib helped over 58% of patients achieve significant hair regrowth within 12 months.
- The drug was generally well-tolerated, with acne being the moast common side effect.
- Earlier treatment and lower disease severity at the start of therapy were linked to better outcomes.
- Many patients had already tried multiple treatments before starting baricitinib, highlighting the challenges of managing severe alopecia areata.
What is alopecia areata, and how does baricitinib work? Alopecia areata is an autoimmune disorder where the immune system mistakenly attacks hair follicles, leading to hair loss. Baricitinib is a Janus kinase (JAK) inhibitor, wich works by suppressing the immune system’s attack on these follicles, allowing hair to regrow.
The prospective observational study, published in the journal of Dermatologic Treatment on December 27, 2024, followed 48 adults with severe alopecia areata for one year to evaluate how well baricitinib worked in a “real-world” setting-meaning outside of highly controlled clinical trials. 1 The primary goal was to see how many patients achieved a Severity of Alopecia tool (SALT) score below 20%,a measure of significant hair regrowth,and to maintain that betterment for at least 12 weeks.
The participants, with an average age of 37, were largely female (66.7%), which aligns with the typical patient profile for alopecia areata. They had been battling the condition for an average of nearly 11 years, and most had already tried a range of treatments, including topical and systemic steroids, minoxidil, methotrexate, and even another JAK inhibitor, tofacitinib (in 20.8% of cases). Many also had other autoimmune conditions like hypothyroidism (22.9%) and atopic dermatitis (18.8%).
Most patients (87.5%) started on the standard dose of 4 mg of baricitinib per day, with a smaller group beginning at 2 mg/day. Some required dose adjustments based on how they were responding or if they experienced side effects.
Over the year, average SALT scores dropped dramatically, from 67% at the beginning to 22% at the 12-month mark (P < .001), with the biggest improvements seen in the frist six months. By months 9 and 12, 58.3% of patients had reached the primary endpoint of a SALT score under 20. A complete response, with a SALT score below 10, was seen in 37.5% of participants.
